Nurix Therapeutics

Nurix’s Senior Scientist of Medicinal Chemistry, Tim Kane, will present a poster on Nurix’s approach to discovering IRAK4 targeted protein degraders at the American Chemical Society Fall meeting taking place August 18-22, 2024. Learn more about this year’s meeting here: https://bit.ly/4d8ew1I #ACSFall2024

In the U.S., lung cancers account for 1 in 5 of all cancer deaths. At Nurix, we’re using our targeted protein modulation platform to potentially improve outcomes for those facing a diagnosis of cancer, including lung cancer. https://bit.ly/3L7kMKK #WorldLungCancerDay 

Today, Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will discuss the latest company updates in a fireside chat at the UBS Virtual Targeted Protein Degradation Day at 2:30 p.m. ET.     Listen to the live or archived discussion here: https://lnkd.in/eecFcZyK

We continued to make solid progress in the second quarter of 2024, including reporting new positive clinical data on NX-5948 at #EHA2024 and strengthening our balance sheet with a $188M public offering.    Learn more about our progress and future plans here:  https://lnkd.in/e4fmcsBR

At #EHA2024 we presented new clinical data from the Phase 1a/b trial of BTK degrader, NX-5948 in relapsed or refractory B-cell malignancies.     Data presented demonstrated an ORR of 69.2% in a heavily pretreated patient population of CLL patients and clinical responses were rapid and deepening with longer time on treatment.     Read more in the full press release here: https://bit.ly/3VIT6Cf

Nurix team members are enjoying attending the Biotechnology Innovation Organization Convention. It's always a great time connecting with industry leaders, exploring groundbreaking innovations, and forging new partnerships that will shape the future of biotechnology. #BIO2024

Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 5:30 p.m. ET. Listen to the live or archived presentation here: https://bit.ly/3yRXPZi

National Cancer Survivors Day is an annual, worldwide celebration to recognize cancer survivors, bring awareness to the ongoing challenges survivors face, and most importantly, celebrate life. At Nurix, we are developing novel therapies to potentially change the treatment landscape and increase the number of survivors of cancer. #NCSD #CancerSurvivorsDay

Nurix’s Research Associate of Analytical Chemistry, Shalya Masters, will present a poster presentation at the 36th International Symposium on Preparative and Process Chromatography taking place May 28-31, 2024. Learn more about the symposium here: https://www.prep2024.org/ #PREP2024

Nurix’s Senior Scientist of Analytical Chemistry, Amber Guillen, will present at the 36th International Symposium on Preparative and Process Chromatography on Thursday, May 30th at 3:00 p.m. ET. Learn more about the symposium here: https://www.prep2024.org/ #PREP2024